Yes, Victoza is a GLP-1 receptor agonist. Its active ingredient, liraglutide, mimics a natural hormone called GLP-1 (glucagon-like peptide-1) that your body produces in the gut after eating. Victoza was one of the earlier GLP-1 medications to reach the market and remains widely prescribed for type 2 diabetes.
How Victoza Works as a GLP-1 Drug
Your body naturally releases GLP-1 after meals to help regulate blood sugar. Liraglutide, the active compound in Victoza, activates the same receptors that natural GLP-1 targets, but it lasts much longer in your system. The drug lowers blood sugar through three main pathways: it signals your pancreas to release more insulin when glucose is high, it reduces the amount of glucagon (a hormone that raises blood sugar) your body produces, and it slows the rate at which food leaves your stomach. That slower gastric emptying is also why many people on GLP-1 drugs feel full longer after eating.
An important feature of liraglutide is that its insulin-boosting effect is glucose-dependent. This means it ramps up insulin production when blood sugar is elevated but backs off as levels return to normal, which lowers the risk of dangerous blood sugar drops compared to some other diabetes medications.
What Victoza Is Approved For
Victoza is FDA-approved as an add-on treatment for type 2 diabetes in adults and in children aged 10 and older. Beyond blood sugar control, it also carries an indication for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. In the large LEADER clinical trial, liraglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 13% compared to placebo in patients with type 2 diabetes and high cardiovascular risk.
Victoza is not approved for weight loss on its own or for type 1 diabetes. However, liraglutide is also sold under a different brand name, Saxenda, specifically for weight management. Saxenda uses the same molecule at a higher maximum dose (3 mg daily versus Victoza’s 1.8 mg daily).
Dosing and What to Expect
Victoza is a once-daily injection given under the skin, typically in the abdomen, thigh, or upper arm. The starting dose is 0.6 mg per day for the first week. This initial dose isn’t meant to control blood sugar on its own; it’s a ramp-up period to help your body adjust and minimize side effects. After that first week, the dose increases to 1.2 mg daily. If you need more blood sugar control, your prescriber may raise it to the maximum of 1.8 mg daily after at least another week.
Children aged 10 and older follow the same starting dose and the same 0.6 mg step-up increments, with the same 1.8 mg maximum.
How Victoza Compares to Ozempic
Both Victoza and Ozempic are GLP-1 receptor agonists for type 2 diabetes, but they use different active ingredients. Victoza contains liraglutide and requires a daily injection. Ozempic contains semaglutide and is injected once a week, which many people find more convenient.
In terms of blood sugar reduction, Victoza typically lowers A1c by 0.8% to 1.5%, while Ozempic tends to deliver a larger reduction of 1.2% to 2.1%. Both medications slow gastric emptying and reduce appetite, but the stronger A1c results and weekly dosing have made Ozempic the more commonly discussed option in recent years. That said, Victoza has a longer track record and more post-market safety data, including the LEADER cardiovascular outcomes trial.
Common Side Effects
The most frequently reported side effects are gastrointestinal. Nausea is the most common, especially during the first few weeks as your body adjusts and while doses are being increased. Vomiting, diarrhea, constipation, decreased appetite, and indigestion also show up regularly in clinical trial data. For most people, these effects are mild to moderate and tend to improve over time. The gradual dose titration schedule exists specifically to reduce the severity of these symptoms.
The Thyroid Warning
Victoza carries a boxed warning (the most serious type of FDA warning) related to thyroid tumors. In animal studies, liraglutide caused thyroid C-cell tumors in mice and rats, particularly at doses about eight times higher than the human dose. Whether this risk translates to humans isn’t fully established, but as a precaution, Victoza is contraindicated in people with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Every prescription comes with a medication guide explaining this risk and the symptoms to watch for, which include a lump or swelling in the neck, difficulty swallowing, hoarseness, and shortness of breath.